ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,413.57
-0.30%
Dow Jones
39,869.38
-0.10%
Gold vs US Dollar
2,386.325
0.34%
Brent Oil
83.135
-0.08%
Bitcoin
66,257.33
1.56%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Prime Medicine Inc (PRME)

  7. Prime Medicine Inc (PRME) News

Prime Medicine (PRME)

Prime Medicine Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PRME
DateTimeSourceHeadlineSymbolCompany
13/05/202413:00GlobeNewswire Inc.Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQNASDAQ:PRMEPrime Medicine Inc
10/05/202413:22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRMEPrime Medicine Inc
10/05/202413:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
10/05/202413:00GlobeNewswire Inc.Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:PRMEPrime Medicine Inc
08/05/202413:00GlobeNewswire Inc.Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)NASDAQ:PRMEPrime Medicine Inc
01/05/202413:00GlobeNewswire Inc.Prime Medicine to Participate in the 27th Annual Milken Institute Global ConferenceNASDAQ:PRMEPrime Medicine Inc
29/04/202412:00GlobeNewswire Inc.Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)NASDAQ:PRMEPrime Medicine Inc
23/04/202413:00GlobeNewswire Inc.Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific MeetingsNASDAQ:PRMEPrime Medicine Inc
01/03/202413:09Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PRMEPrime Medicine Inc
01/03/202413:04Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PRMEPrime Medicine Inc
01/03/202413:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
01/03/202413:00GlobeNewswire Inc.Prime Medicine Reports Full Year 2023 Financial Results and Provides Business UpdatesNASDAQ:PRMEPrime Medicine Inc
28/02/202413:00GlobeNewswire Inc.Prime Medicine to Participate in Upcoming Investor ConferencesNASDAQ:PRMEPrime Medicine Inc
23/02/202422:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRMEPrime Medicine Inc
23/02/202422:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRMEPrime Medicine Inc
23/02/202402:31Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:PRMEPrime Medicine Inc
20/02/202422:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRMEPrime Medicine Inc
20/02/202421:01GlobeNewswire Inc.Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesNASDAQ:PRMEPrime Medicine Inc
16/02/202411:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
16/02/202411:17Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PRMEPrime Medicine Inc
15/02/202404:50GlobeNewswire Inc.Prime Medicine Announces Pricing of Upsized Public OfferingNASDAQ:PRMEPrime Medicine Inc
15/02/202402:57Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:PRMEPrime Medicine Inc
14/02/202422:27Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PRMEPrime Medicine Inc
14/02/202421:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
14/02/202421:05GlobeNewswire Inc.Prime Medicine Announces Proposed Public Offering of Common StockNASDAQ:PRMEPrime Medicine Inc
25/01/202413:00GlobeNewswire Inc.Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic FibrosisNASDAQ:PRMEPrime Medicine Inc
08/01/202413:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
05/01/202422:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
05/01/202413:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
05/01/202413:00GlobeNewswire Inc.Prime Medicine Appoints Allan Reine, M.D., as Chief Financial OfficerNASDAQ:PRMEPrime Medicine Inc
 Showing the most relevant articles for your search:NASDAQ:PRME

Your Recent History

LSE
CAT
Catco Reinsurance Opport...
BTRX
DMTBTC
DMarket
NYSE
MFAC.U
Megalith Financial Acqui...
BOV
MGLUT210
MGLUT210 Ex:2,09
COIN
VAIIIUSD
VAIOT Token
NYSE
GNW
Genworth Financial
LSE
JPIZ
LSE
ECR
Ecr Minerals
COIN
BNSOLDUSD
BNS Token [OLD]
NASDAQ
DRMA
Dermata Therapeutics
BIT
I08994
Intesa Sanpaolo
LSE
0A08
Ishares J.p. Morgan Usd ...
BIT
AT1D
Invesco AT1 Capital Bond...
NASDAQ
BCRX
BioCryst Pharmaceuticals
COIN
LUNAUSD
Terra
ASX
CYQDE
Warrants 31/03/2023
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved